News | March 23, 2024
USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Subscribe To Our Newsletter & Stay Updated
